Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201904-19 Lead Optimization of Anti-c-Met Agonistic Antibody for Treatment of Ischemic Retinal Diseases(Others, Protein) [2019-09-27]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

To develop the lead of anti-c-Met agonistic antibody to treat ischemic retinal diseases via promoting physiological angiogenesis

Unmet Medical Need & Target Patients

Target patients: Patients with ischemic retinal diseases

 

Unmet medical needs

- Current treatment options for ischemic retinal diseases are restricted to therapeutic injections that refrain vascular endothelial growth factors from promoting pathological neovasculization.

Status

Lead generation

Intellectual Property

Establishment of intellectual property strategy

Competitive Advantages

-There are no drugs promoting physiological angiogenesis for the treatment of ischemic retinal diseases in developmental stages.

-There are no generic or biosimilar drugs of c-Met agonists.

Contact & Company Overview

  • Company Name :
    Seoul National University R&DB Foundation
  • Homepage :
  • Contact Person :
    Dong Hyun Jo
  • Contact :
    82-2-2072-1774

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code